The Queen Elizabeth Hospital Charity exists to support medical and health research, and to encourage excellence in healthcare for patients and their care givers, wholly or mainly through the services provided by University Hospital Birmingham NHS Foundation Trust. It raises money for campaigns that are over and above what the NHS can provide. QEH Charity was formed in 2001, however there has been an official charity associated with the Queen Elizabeth Hospital since the creation of the NHS in 1948. The charity will become independent in April 2016..
Background:Major adverse cardiovascular events (MACE) are common early after liver transplantation (LT) as reported in the United States, but incidence is not well described in a European cohort. With lower MACE rates reported after kidney transplantation in the United Kingdom versus the United States, it is important to determine if a similar incongruity exists after LT. Methods:In this large retrospective, population cohort study, we studied all LT procedures performed in England between 1st April 2002 and 31st March 2023 (n = 10,213). MACE data was obtained from Hospital Episode Statistics, an administration data warehouse for any hospitalization to English NHS hospital, and defined as any of the following: myocardial infarction, stroke, unstable angina, heart failure, any coronary revascularization procedure and any cardiovascular-defined death. Findings:MACE-related 1-year mortality was low at 0.1% (n = 11). Overall, MACE occurred in 268 (2.6%) LT recipients within the first year after LT, of which 125 (1.2%) occurred within the first month. The commonest observed MACE was stroke (n = 129, 1.3%), followed by myocardial infarction (n = 89, 0.9%). After adjustment, MACE within the first year was associated with increased risk for long-term all-cause mortality (Hazard Ratio 1.37, 95% CI 1.05-1.79, p = 0.021). In a competing risk regression model, with non-cardiac death a competing risk, the following were independently associated with increased risk of MACE after LT: increasing age, male sex, diabetes, and higher Charlson co-morbidity score. Interpretation:MACE and cardiovascular death are uncommon within the first-year post LT in England. However, liver transplant recipients with non-fatal MACE have inferior long-term survival. Further work is warranted to determine the best strategy to mitigate cardiac risk stratification for LT candidates and evidence-based strategies to mitigate cardiovascular risk after LT must be encouraged. Funding:Nothing to disclose.
Abstract Introduction Gliolan is used to enhance visualisation during high-grade glioma resection and is reimbursed through activity-based tariff mechanisms within the National Health Service. Funding is derived from a higher tariff charged directly to NHS England (NHSE). Correct clinical coding is essential to ensure appropriate tariffs are charged and to ensure the service provided is financially sustainable. Each case of mis-coding which results in the incorrect tariff being applied may cost up to £2533. Method Neuro-oncology MDT outcomes from June–August 2025 were retrospectively reviewed to identify patients undergoing tumour resection. Operative documentation was reviewed to confirm recording of Gliolan administration within noting and/or a separate operation note (“Introduction of photodynamic substance into organ, NOC”). Patient identifiers were provided to the coding team to confirm final HRG allocation and tariff received. Findings were compared with data from the same period in 2024. Following the first audit cycle, teaching was delivered to the coding team. Results From June-August 2024, 15 patients underwent surgery with Gliolan. 40% were correctly coded. Eight patients missed additional income due to absence of the supplementary code; one was incorrectly coded; three had correct coding; and three received the AA51 tariff due to complexity. From June-August 2025, 11 patients were identified. Ten (91%) were correctly coded and one non-elective case was not initially coded for Gliolan; this was corrected. The total loss prevented over the 2025 audit period was £30,550.32. Conclusion Due to not being locally contractually allocated, accurate application of supplementary coding is essential to recover centrally commissioned income. Following education of the coding team, correct coding improved from 40% in 2024 to 91% in 2025, demonstrating the organisational impact collaboration between clinical teams and coders can have.